Literature DB >> 15033667

Clinical outcome after laparoscopic pure management of borderline ovarian tumors: results of a series of 34 patients.

S Camatte1, P Morice, D Atallah, A Thoury, P Pautier, C Lhommé, P Duvillard, D Castaigne.   

Abstract

BACKGROUND: The aim of this study was to assess clinical outcome after laparoscopic treatment of borderline ovarian tumor (BOT). PATIENTS AND METHODS: Thirty-four patients treated initially and/or for recurrent disease using a laparoscopic approach for BOT from 1984 to January 2002.
RESULTS: Thirty-four patients underwent laparoscopic pure treatment (without conversion by laparotomy and/or reassessment surgery by laparotomy) for BOT. Conservative treatment was performed in 31 (91%) patients. Median follow-up time was 45 months (range 6-228). Six (17%) patients recurred (in the remaining ovary following conservative surgery in five patients and in the peritoneum in one patient). Two port-site metastases were observed. None of the patients had recurrent disease in the form of ovarian carcinoma. Nine spontaneous pregnancies were observed in six patients from a group of 15 patients desiring pregnancy. All patients are alive today and disease-free.
CONCLUSION: These results seem to demonstrate that laparoscopic treatment can be safely performed in young patients with early stage BOT. Such a procedure is then feasible, but should be evaluated in patients with BOT and peritoneal implants.

Entities:  

Mesh:

Year:  2004        PMID: 15033667     DOI: 10.1093/annonc/mdh149

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  2 in total

Review 1.  Role of minimally invasive surgery in staging of ovarian cancer.

Authors:  David A Iglesias; Pedro T Ramirez
Journal:  Curr Treat Options Oncol       Date:  2011-09

Review 2.  Controversies in borderline ovarian tumors.

Authors:  Seok Ju Seong; Da Hee Kim; Mi Kyoung Kim; Taejong Song
Journal:  J Gynecol Oncol       Date:  2015-09-23       Impact factor: 4.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.